ACTA1 and inflammation: Studies have revealed that in a mouse model of pulmonary fibrosis, treatment with CEP can ameliorate BLM-induced lung inflammation and the lung coefficient, while also reducing the expression levels of M2 macrophage marker CD206 in lung tissue, as well as the expression levels of α-SMA, fibronectin, and collagen I[244].